Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 36Lymphoid 8Sarcoma 3Other hematologic neoplasm 3Dermatologic 2Thoracic 1

Conditions

Melanoma 2Uveal Melanoma 1Brain Neoplasms 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lomustine × Dermatologic × Clear all
NCT00527657 2018-11-14

Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients

M.D. Anderson Cancer Center

Phase 1 Completed
17 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡